{"id":63535,"date":"2026-04-20T14:27:06","date_gmt":"2026-04-20T06:27:06","guid":{"rendered":"https:\/\/flcube.com\/?p=63535"},"modified":"2026-04-20T14:27:07","modified_gmt":"2026-04-20T06:27:07","slug":"xuanzhu-biopharmaceutical-reports-landmark-phase-iii-diamond-2-results-for-xuanfeining-dirozalkib-in-alk-positive-nsclc-31-3-month-pfs-doubles-crizotinib-standard-at-aacr-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63535","title":{"rendered":"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026"},"content":{"rendered":"\n<p><strong>Xuanzhu Biopharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2575:HKG\">HKG: 2575<\/a>) unveiled pivotal <strong>Phase III DIAMOND-2 trial results<\/strong> for <strong>Xuanfeining<\/strong> (dirozalkib), a next-generation oral <strong>ALK inhibitor<\/strong>, as first-line treatment for <strong>ALK-positive advanced non-small cell lung cancer<\/strong> (NSCLC) at the <strong>2026 American Association for Cancer Research<\/strong> (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a <strong>31.3-month median progression-free survival<\/strong> (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-development-timeline\">Regulatory &amp; Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>Xuanfeining (dirozalkib)<\/td><\/tr><tr><td><strong>Approval Status<\/strong><\/td><td>Approved in China (August 2025) for ALK-positive locally advanced or metastatic NSCLC<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line treatment for ALK-positive advanced NSCLC<\/td><\/tr><tr><td><strong>Clinical Presentation<\/strong><\/td><td>AACR Annual Meeting 2026 (oral presentation)<\/td><\/tr><tr><td><strong>Trial Designation<\/strong><\/td><td>DIAMOND-2 Phase III study<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-design-amp-methodology\">Trial Design &amp; Methodology<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Type:<\/strong> Multicenter, randomized, open-label Phase III clinical trial<\/li>\n\n\n\n<li><strong>Geographic Scope:<\/strong> Conducted exclusively in China<\/li>\n\n\n\n<li><strong>Comparator:<\/strong> Head-to-head versus crizotinib (current first-line standard)<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> ALK-positive advanced NSCLC patients, treatment-na\u00efve to ALK inhibitors<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Investigator-assessed median progression-free survival (mPFS)<\/li>\n\n\n\n<li><strong>Analysis Population:<\/strong> Modified intention-to-treat (mITT) population<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-efficacy-results-unprecedented-pfs-benefit\">Efficacy Results \u2013 Unprecedented PFS Benefit<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Efficacy Parameter<\/th><th>Dirozalkib Group<\/th><th>Crizotinib Group<\/th><th>Hazard Ratio\/Improvement<\/th><\/tr><\/thead><tbody><tr><td><strong>Median PFS<\/strong><\/td><td><strong>31.3 months<\/strong><\/td><td><strong>12.9 months<\/strong><\/td><td><strong>HR 0.47 (53% risk reduction)<\/strong><\/td><\/tr><tr><td><strong>Objective Response Rate<\/strong> (ORR)<\/td><td><strong>88.5%<\/strong><\/td><td>Not specified<\/td><td>Significantly superior<\/td><\/tr><tr><td><strong>Median Duration of Response<\/strong> (mDoR)<\/td><td><strong>32.10 months<\/strong><\/td><td>Not specified<\/td><td>Significantly superior<\/td><\/tr><tr><td><strong>Disease Control Rate<\/strong> (DCR)<\/td><td><strong>95.4%<\/strong><\/td><td>Not specified<\/td><td>Significantly superior<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The <strong>53% reduction in disease progression risk<\/strong> represents one of the most substantial improvements ever demonstrated in ALK-positive NSCLC first-line therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-intracranial-activity-addressing-critical-unmet-need\">Intracranial Activity \u2013 Addressing Critical Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Intracranial Endpoint<\/th><th>Dirozalkib Group<\/th><th>Crizotinib Group<\/th><\/tr><\/thead><tbody><tr><td><strong>Intracranial ORR<\/strong> (IC-ORR)<\/td><td><strong>91.7%<\/strong><\/td><td><strong>11.1%<\/strong><\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Measurable baseline intracranial lesions<\/td><td>Measurable baseline intracranial lesions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Dirozalkib&#8217;s <strong>91.7% intracranial response rate<\/strong> dramatically outperforms crizotinib&#8217;s 11.1%, addressing a critical limitation of current ALK inhibitors in managing brain metastases, which occur in up to 60% of ALK-positive NSCLC patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-profile-favorable-tolerability\">Safety Profile \u2013 Favorable Tolerability<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Overall Safety:<\/strong> Demonstrated favorable safety and tolerability profile<\/li>\n\n\n\n<li><strong>Comparison Context:<\/strong> Next-generation ALK inhibitors typically show improved CNS penetration with manageable toxicity compared to first-generation agents like crizotinib<\/li>\n\n\n\n<li><strong>Clinical Implication:<\/strong> Enhanced safety profile supports long-term treatment adherence and quality of life<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ALK-Positive NSCLC Market:<\/strong> Represents approximately <strong>3-7% of all NSCLC cases<\/strong> globally, with an estimated <strong>40,000 new ALK-positive cases annually<\/strong> in major markets<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Dirozalkib competes with other next-generation ALK inhibitors including alectinib (Alecensa), brigatinib (Alunbrig), and lorlatinib (Lorbrena)<\/li>\n\n\n\n<li><strong>Market Differentiation:<\/strong> The <strong>31.3-month PFS<\/strong> significantly exceeds historical benchmarks from other next-generation ALK inhibitors (typically 25-34 months), potentially establishing dirozalkib as the new first-line standard<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> Strong Phase III data positions Xuanzhu for international regulatory filings and potential partnership opportunities with global pharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for Xuanfeining (dirozalkib). Actual results may differ due to risks including regulatory decisions, competitive dynamics, market adoption rates, and potential confirmatory trial requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041900008_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026041900008_c.\"><\/object><a id=\"wp-block-file--media-0c16dec1-2c8e-4648-aa5e-877eddb1dffe\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041900008_c.pdf\">2026041900008_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041900008_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0c16dec1-2c8e-4648-aa5e-877eddb1dffe\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,4408,670],"class_list":["post-63535","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-hkg-2575","tag-xuanzhu-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining (dirozalkib), a next-generation oral ALK inhibitor, as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a 31.3-month median progression-free survival (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63535\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026\" \/>\n<meta property=\"og:description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining (dirozalkib), a next-generation oral ALK inhibitor, as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a 31.3-month median progression-free survival (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63535\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T06:27:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T06:27:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63535#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63535\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026\",\"datePublished\":\"2026-04-20T06:27:06+00:00\",\"dateModified\":\"2026-04-20T06:27:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63535\"},\"wordCount\":486,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"HKG: 2575\",\"Xuanzhu Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63535#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63535\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63535\",\"name\":\"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-20T06:27:06+00:00\",\"dateModified\":\"2026-04-20T06:27:07+00:00\",\"description\":\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining (dirozalkib), a next-generation oral ALK inhibitor, as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a 31.3-month median progression-free survival (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63535#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63535\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63535#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining (dirozalkib), a next-generation oral ALK inhibitor, as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a 31.3-month median progression-free survival (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63535","og_locale":"en_US","og_type":"article","og_title":"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026","og_description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining (dirozalkib), a next-generation oral ALK inhibitor, as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a 31.3-month median progression-free survival (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.","og_url":"https:\/\/flcube.com\/?p=63535","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-20T06:27:06+00:00","article_modified_time":"2026-04-20T06:27:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63535#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63535"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026","datePublished":"2026-04-20T06:27:06+00:00","dateModified":"2026-04-20T06:27:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63535"},"wordCount":486,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Clinical trial results","HKG: 2575","Xuanzhu Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63535#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63535","url":"https:\/\/flcube.com\/?p=63535","name":"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-20T06:27:06+00:00","dateModified":"2026-04-20T06:27:07+00:00","description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining (dirozalkib), a next-generation oral ALK inhibitor, as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a 31.3-month median progression-free survival (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63535#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63535"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63535#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC \u2013 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63535"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63535\/revisions"}],"predecessor-version":[{"id":63537,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63535\/revisions\/63537"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}